Eli Lilly and Company
Founded Year
1876Stage
IPO | IPODate of IPO
1/1/1952Market Cap
917.64BStock Price
1025.28Revenue
$0000About Eli Lilly and Company
Eli Lilly and Company operates as a pharmaceutical company. It is involved in developing medicines using biotechnology, chemistry, and genetic medicine to improve health outcomes. The company serves the healthcare sector with its pharmaceutical products. It was founded in 1876 and is based in Indianapolis, Indiana.
Loading...
ESPs containing Eli Lilly and Company
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The D2C prescription weight loss & metabolic services market offers weight loss and metabolic management services directly to consumers, typically without the need for traditional healthcare provider involvement. These services often utilize digital platforms, telemedicine, and personalized approaches to provide convenient, accessible, and evidence-based solutions for individuals seeking to manage…
Eli Lilly and Company named as Highflier among 15 other companies, including Amazon, Novo Nordisk, and Omada Health.
Loading...
Research containing Eli Lilly and Company
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Eli Lilly and Company in 7 CB Insights research briefs, most recently on Jul 3, 2025.
May 23, 2025
The AI in drug R&D market map
Expert Collections containing Eli Lilly and Company
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Eli Lilly and Company is included in 2 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
HLTH 2025 Exhibitors
878 items
A look at the HLTH Vegas 2025 exhibitor list we’ve been building so your team can start scanning for relevant companies.
Eli Lilly and Company Patents
Eli Lilly and Company has filed 1028 patents.
The 3 most popular patent topics include:
- medical equipment
- diabetes
- drug delivery devices
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/11/2023 | 4/8/2025 | Peptide hormones, Obesity, Potassium channel blockers, G protein coupled receptors, Diabetes | Grant |
Application Date | 10/11/2023 |
|---|---|
Grant Date | 4/8/2025 |
Title | |
Related Topics | Peptide hormones, Obesity, Potassium channel blockers, G protein coupled receptors, Diabetes |
Status | Grant |
Latest Eli Lilly and Company News
Nov 16, 2025
基因編輯不只治罕病，Crispr 療法首度攻克高膽固醇 在基因編輯技術的最新進展中，瑞士生技公司 Crispr Therapeutics 開發的一種實驗性基因編輯療法成功地將高膽固醇水準降低了一半，為心臟病的治療帶來了新的希望。 這項臨床試驗共招募了15名參與者，他們接受了一次性注射，旨在關閉肝臟中的一種名為ANGPTL3的基因。ANGPTL3基因調節脂質代謝，透過抑制脂蛋白脂肪酶（LPL）和內皮脂肪酶（EL）來影響三酸甘油酯和低密度脂蛋白膽固醇（LDL-C）的水準。這種基因的突變在少數人中可以自然保護他們免受心臟病的影響，且不會產生明顯的副作用。試驗中使用的最高劑量在治療後兩週內，平均將壞膽固醇（LDL）和三酸甘油酯的水準降低了50%。這個效果至少持續了60天，與試驗的持續時間相符。 Crispr技術自獲得諾貝爾獎以來，主要用於治療罕見疾病，但這些最新的發現顯示，這一DNA編輯工具也可能用於治療更常見的健康問題。該公司目前擁有市場上唯一獲批的基因編輯療法Casgevy，該療法用於治療鎌狀細胞病和β地中海貧血。 根據美國心臟協會的估計，約四分之一的美國成年人膽固醇水準偏高，三酸甘油酯水準也相似。LDL膽固醇是血液中的一種蠟狀物質，隨著時間的推移可能會導致動脈堵塞和硬化，而三酸甘油酯則是體內最常見的脂肪類型。這兩者的高水準都會增加心臟病和中風的風險。 這項I期試驗於2024年6月至2025年8月在英國、澳洲和紐西蘭進行，參與者年齡介於31至68歲之間，且LDL膽固醇和三酸甘油酯水準失控。試驗測試了五種不同劑量的Crispr注射，平均需要約兩個半小時來施用。 在試驗中，一名51歲的男性參與者在接受最低劑量的治療後六個月去世，這與膽固醇和三酸甘油酯的降低無關，而是與他已有的心臟病有關。這名男子患有罕見的遺傳性高膽固醇，並曾多次接受改善心臟血流的手術。 在試驗中，三名參與者出現了輕微的反應，如背痛和噁心，經過藥物治療後消失。另一名參與者在接受Crispr注射前肝酶升高，注射後肝酶暫時上升幾天，隨後恢復正常，無需治療。 研究人員將在試驗結束後持續監測參與者一年，並根據美國食品藥品監督管理局的建議，進行長達15年的安全性隨訪。團隊計劃在2026年進行II期研究，將包括更廣泛的患者群體和更長的隨訪期。希望一次Crispr注射的效果能持續多年，甚至永久，取代每日服用藥物或定期注射的需求。 這並不是首次使用基因編輯技術來解決心血管疾病。Verve Therapeutics正在使用一種新型的Crispr技術，稱為基因編輯，針對一種名為PCSK9的基因，專門針對遺傳性高膽固醇和早發性心臟病患者。Verve在2024年暫停了一項基因編輯候選者的試驗，因為一名參與者的肝酶升高引起了擔憂，但今年顯示出14名患者的新療法的安全性數據。早些時候，艾利利宣布以超過10億美元的價格收購Verve。 安全性是新基因編輯療法的一個關鍵問題。Intellia Therapeutics在一名患者因肝損傷去世後暫停了Crispr治療的試驗。由於許多Crispr療法針對肝臟，因此肝損傷已知是一個風險。
Eli Lilly and Company Frequently Asked Questions (FAQ)
When was Eli Lilly and Company founded?
Eli Lilly and Company was founded in 1876.
Where is Eli Lilly and Company's headquarters?
Eli Lilly and Company's headquarters is located at Lilly Corporate Center, Indianapolis.
What is Eli Lilly and Company's latest funding round?
Eli Lilly and Company's latest funding round is IPO.
Who are the investors of Eli Lilly and Company?
Investors of Eli Lilly and Company include Kleiner Perkins and SV Health Investors.
Who are Eli Lilly and Company's competitors?
Competitors of Eli Lilly and Company include Turning Point Therapeutics, GlaxoSmithKline - Antibiotics Business Cephalosporin, Viatris, Moderna, Novartis and 7 more.
Loading...
Compare Eli Lilly and Company to Competitors
Boehringer Ingelheim operates within the pharmaceutical and animal health sectors. The company conducts research and development of products for humans and animals. Boehringer Ingelheim serves the healthcare industry with an emphasis on pharmaceutical products. It was founded in 1885 and is based in Ingelheim am Rhein, Germany.
Servier operates as a pharmaceutical company, engages in the research, development, and production of medications for various diseases, including targeted therapies for cancer, cardiovascular treatments, diabetes, and drugs for immuno-inflammatory and neuropsychiatric conditions. The company also produces generic drugs. It was founded in 1954 and is based in Suresnes, France.
Novartis develops and offers a range of medicines aimed at treating serious diseases, providing support for patients and healthcare professionals, and conducting research to discover new therapies. The company also focuses on environmental sustainability and ethical practices in the pharmaceutical industry. It was founded in 1996 and is based in Basel, Switzerland.
Bristol-Myers Squibb operates as a biopharmaceutical company involved in the discovery, development, and delivery of medicines across various therapeutic areas. The company specializes in treatments for oncology, hematology, immunology, cardiovascular disease, and fibrosis, utilizing translational medicine and data analytics. Bristol-Myers Squibb also engages in health equity initiatives through its foundation to improve health outcomes for populations affected by serious diseases. It was founded in 1887 and is based in Princeton, New Jersey.
Pfizer is a biopharmaceutical company involved in the discovery, development, and manufacturing of medications and vaccines aimed at improving health outcomes. The company serves the healthcare sector with its medical solutions. It is based in Jakarta, Indonesia.
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was formerly known as Sumitomo Dainippon Pharma. It was founded in 1897 and is based in Osaka, Japan.
Loading...